Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Richard A. Larson(Urbana University), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Richard E. Clark(The Football Association), Giuseppe Saglio(University of Turin), Andreas Hochhaus(Jena University Hospital), Timothy P. Hughes(Royal Adelaide Hospital), Ian W. Flinn(Tennessee Oncology), Rick E. Blakesley(Novartis (Switzerland)), Gabriel Étienne(Institut Bergonié), Mineo Kurokawa(University of Tokyo Hospital), R. Yu(Novartis (Switzerland)), Beatriz Moiraghi(Hospital Ramos Mejía), Neil J. Gallagher(Yale University)
Cited by 440
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k